Erica Burnett
Family · Warner Robins, GANPI 1659649515
Payments from drug & device makers
Across 490 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$1K
- Lilly USA, LLC$735
- Boehringer Ingelheim$618
- Xeris Pharmaceuticals, Inc.$580
- Abbott$445
- plus $6K from 33 others
What the payments were for
- Food & beverage$10,51398%
- Education$1121%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 48 | $1,356 |
| Novo Nordisk | 62 | $1,267 |
| Lilly USA, LLC | 42 | $735 |
| Boehringer Ingelheim | 24 | $618 |
| Xeris Pharmaceuticals, Inc. | 15 | $580 |
| Abbott | 26 | $445 |
| Corcept Therapeutics | 18 | $373 |
| Bayer | 18 | $353 |
| Cequr Corporation | 4 | $333 |
| Sanofi-aventis U.S. LLC | 17 | $331 |
| IBSA Pharma Inc. | 17 | $326 |
| Bigfoot Biomedical Inc | 3 | $306 |
| Insulet Corporation | 15 | $300 |
| Medtronic | 14 | $292 |
| AstraZeneca(2 entities) | 16 | $289 |
| Esperion Therapeutics, Inc. | 10 | $282 |
| Amneal Pharmaceuticals LLC | 14 | $267 |
| Antares Pharma, Inc. | 15 | $255 |
| Mannkind Corporation | 11 | $224 |
| Tandem Diabetes Care, Inc. | 11 | $213 |
| Boston Scientific | 13 | $206 |
| Dexcom, Inc. | 11 | $204 |
| Novartis | 10 | $179 |
| AbbVie | 11 | $159 |
| Zealand Pharma US, Inc. | 7 | $104 |
| Madrigal Pharmaceuticals | 4 | $96 |
| Kyowa Kirin, Inc. | 4 | $87 |
| Radius Health, Inc. | 4 | $75 |
| Clarus Therapeutics Inc. | 7 | $69 |
| Tolmar, Inc. | 3 | $56 |
| Sequel Med Tech, LLC | 2 | $50 |
| Pfizer | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Recordati_rare_diseases_inc. | 2 | $36 |
| Ascendis Pharma Endocrinology Inc | 2 | $35 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UNITY DIABETES MANAGEMENT SYSTEM$294
- Repatha$240
- GVOKE PFS$233
- JARDIANCE$230
- TEPEZZA$226
- CeQur Simplicity$135
- NEXLIZET$125
- NEXLETOL$125
- MINIMED 780G$121
- RYBELSUS$104
How this compares
$10,684 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 550 | $999,580 |
| Tresiba Flextouch U-200Insulin Degludec | 189 | $267,777 |
| JardianceEmpagliflozin | 189 | $263,552 |
| MounjaroTirzepatide | 176 | $260,519 |
| TrulicityDulaglutide | 108 | $203,983 |
| FarxigaDapagliflozin Propanediol | 190 | $194,172 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 62 | $115,148 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 114 | $105,921 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $77,133 |
| RybelsusSemaglutide | 39 | $73,154 |
| Tresiba Flextouch U-100Insulin Degludec | 83 | $66,771 |
| Humulin R U-500Insulin Regular, Human | 37 | $64,908 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $61,493 |
| JanuviaSitagliptin Phosphate | 34 | $39,235 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $36,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,267 | $1,101,523648 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $735 | $478,949350 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $618 | $405,071329 claims |
| AstraZenecaFarxiga | $289 | $194,172190 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $331 | $115,14862 claims |
| AbbVieSynthroid | $159 | $15,764168 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $267 | $3,107316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Warner Robins
- Kelly MurrayWarner Robins$18K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.